Mesoblast (ASX:MSB) will meet with the U.S. Food and Drug Administration (FDA) next month to discuss new data showing significant reductions in opioid use among patients treated with its investigational cell therapy rexlemestrocel-L for chronic low back pain. …
Mesoblast to meet with U.S. FDA over potential non-opioid treatment for chronic back pain
November 5, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
Prescription medicines at the centre of Trump’s 'Great Healthcare Plan'
January 18, 2026 - - Latest News -
Boehringer Ingelheim again recognised as a top employer across Australia and New Zealand
January 18, 2026 - - Latest News -
The quiet and steady privatisation of this critical public health program
January 18, 2026 - - Latest News -
AbbVie to consolidate Sydney operations with move to CBD headquarters
January 15, 2026 - - Latest News -
Anne Harris steps down after defining leadership during COVID and lasting impact on Medicines Australia
January 14, 2026 - - Latest News -
AusBiotech joins Trade Diversification Network to boost global life sciences partnerships
January 13, 2026 - - Australian Biotech -
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 - - Latest News